One is gemcitabine and nab-paclitaxel (gemcitabine and Abraxane). The other is FOLFIRINOX—a 5-FU–based regimen with irinotecan and oxaliplatin. They both perform similarly. They have different toxicities, different administration, and different wear and tear on patients. And so, when picking between those, we are trying to assess what that patient’s needs are. Watch here . . .
For metastatic pancreas cancer, we’ve gone from a gemcitabine-only world to 2 main recipes that we recommend to patients.